-Lawrence Steinman Researcher Activity Profile

Research Author Detailed Information 

Lawrence Steinman Publication Rate By Year

Lawrence Steinman has published 2 paper(s) in 2006, 20 paper(s) in 2007, 1 paper(s) in 2008, for a total of 23 research publications in total.

Lawrence L Steinman Author Information

LAST NAME: steinman

FIRST NAME: lawrence

INITIALS: L

AFFILIATION:

Papers

Lawrence Steinman's Publication Record

1. Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. Year Published: 2006
Division of Immunology and Rheumatology, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.
2. Tolerizing DNA vaccines for autoimmune arthritis. Year Published: 2006
Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94305, USA.
3. Photogenerated glycan arrays identify immunogenic sugar moieties of Bacillus anthracis exosporium. Year Published: 2007
Carbohydrate Microarray Laboratory, Stanford University School of Medicine, Stanford, CA, USA. dwang1@stanford.edu
4. Heme oxygenase-1 and carbon monoxide suppress autoimmune neuroinflammation. Year Published: 2007
5. Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Year Published: 2007
Center for Neurologic Diseases, Brigham and Women's Hospital, 77 Avenue Louis Pasteur, Boston, Massachusetts 02115, USA.
6. Antigen-specific therapy of multiple sclerosis: the long-sought magic bullet. Year Published: 2007
Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA 94305, USA. steinman@stanford.edu
7. Statins--treatment option for central nervous system autoimmune disease? Year Published: 2007
Department of Neurology and Program in Immunology, University of California, San Francisco, California 94143, USA.
8. Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial. Year Published: 2007
Montreal Neurological Institute, Montreal, Quebec, Canada.
9. Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Year Published: 2007
Department of Neurology and Program in Immunology, University of California, San Francisco, 513 Parnassus Avenue, S-268, San Francisco, California 94143-0435, USA.
10. Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis. Year Published: 2007
Division of Medical Oncology, Department of Medicine, Stanford University, Stanford, CA 94305-5151, USA.
11. Antigen-specific therapy of multiple sclerosis: the long-sought magic bullet. Year Published: 2007
Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA 94305, USA. steinman@stanford.edu
12. Statins--treatment option for central nervous system autoimmune disease? Year Published: 2007
Department of Neurology and Program in Immunology, University of California, San Francisco, California 94143, USA.
13. Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial. Year Published: 2007
Montreal Neurological Institute, Montreal, Quebec, Canada.
14. Nanosensor detection of an immunoregulatory tryptophan influx/kynurenine efflux cycle. Year Published: 2007
Department of Plant Biology, Carnegie Institution, Stanford, California, United States of America.
15. Glia-dependent TGF-beta signaling, acting independently of the TH17 pathway, is critical for initiation of murine autoimmune encephalomyelitis. Year Published: 2007
Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California 94305-5235, USA.
16. Nanosensor detection of an immunoregulatory tryptophan influx/kynurenine efflux cycle. Year Published: 2007
Department of Plant Biology, Carnegie Institution, Stanford, California, United States of America.
17. Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity. Year Published: 2007
18. Nanosensor detection of an immunoregulatory tryptophan influx/kynurenine efflux cycle. Year Published: 2007
Department of Plant Biology, Carnegie Institution, Stanford, California, United States of America.
19. Antigen-specific therapy of multiple sclerosis: the long-sought magic bullet. Year Published: 2007
Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA 94305, USA. steinman@stanford.edu
20. Statins--treatment option for central nervous system autoimmune disease? Year Published: 2007
Department of Neurology and Program in Immunology, University of California, San Francisco, California 94143, USA.
21. Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity. Year Published: 2007
Division of Blood and Marrow Transplantation, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.
22. Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Year Published: 2008
Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California 94305, USA.
23. Glia-dependent TGF-beta signaling, acting independently of the TH17 pathway, is critical for initiation of murine autoimmune encephalomyelitis. Year Published: 2007
Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California 94305-5235, USA.